NCT02833610 2026-02-18
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
4 trialsNCT06374459 2026-02-09
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Phase 1/2 Recruiting
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting